Type II inhibitors, including Cabozantinib, Glesatinib, and Merestinib, not only bind to a hydrophobic pocket beside the ATP binding site of MET but also can block different kinases such as RON, AXL, VEGFR2, etc. Although Cabozantinib was approved for the treatment of advanced medullary thyroid carcinoma and advanced clear-cell renal-cell carcinoma, the studies on the efficacy and safety of Cabozantinib in MET-mutated NSCLC have shown promising results [138]. Here, MET is linked to clear cell renal carcinoma.